VIROSTOP
11.11.2021 12:02:13 CET | Business Wire | Press release
A recent clinical study has shown that the ViroStop nose and throat spray can have a preventative effect against Covid-19 infection, while at the same time boosting the body’s antibody response to the virus. The results support the findings of laboratory tests and an earlier study which also showed the product’s ability to reduce viral shedding and thereby slow the spread of the disease.
Volunteers in the study were all close contacts of someone with a positive PCR test for Covid-19. Out of 189 people 111 used ViroStop and a control group of 78 did not. After 15 days not one of the volunteers using ViroStop gave a positive PCR test while six (roughly 8%) of the control group did. Furthermore, in blood antibody tests, those who took ViroStop were seen to develop immunological protection against Covid-19 in three times more cases than the control group.
Dr István Jankovics, whose team ran the study at Budapest’s Complex Medical Clinic between January and May 2021, commented: “The study confirms our in-vitro (laboratory) tests that ViroStop not only reduces the spread of the virus but can actually help prevent infection in the first place.
The improved immunological response among those with a negative PCR test suggests that the spray reduced the amount of virus in volunteers to such an extent that it could not be detected by PCR but the immune system recognized the virus and produced the specific antibody in response.”
Leading UK expert in primary care, Professor James Kingsland commented: “This is an encouraging development and anything that shows evidence of an additional layer of protection is to be welcomed. The virus is now endemic and rates of infection are still far too high. The best defence is vaccination but anti-viral sprays such as ViroStop can be a useful addition to mask wearing in crowded spaces, social distancing and hand washing.”
The retrospective study took place at the Complex Medical Clinic in Budapest, Hungary between January 15th , and May 31st , 2021 and the results were published in the American publication: Journal of Community Medicine and Public Health Reports. In study of clinical, virological and serological data from patients with mild acute upper respiratory tract infections, a total of 189 volunteers participated. All of the volunteers were close contacts of a COVID-19 PCR positive patient with mild symptoms. Of the 189 individuals, 111 used Virostop after positive PCR analysis of their contact, while 78 did not. All volunteers were tested by PCR assays for SARS CoV-2 at the beginning of the study, and symptoms of each volunteer were checked every two days for 15 days. At the end of the clinical study, each participant underwent a PCR test again for SARS CoV-2, and also a SARS CoV-2 specific IgG antibody assay using the ELISA system, then the symptoms of volunteers were evaluated.
ViroStop made by Swiss company, Herb-Pharma AG comes in the form of a nasal and oral spray. Its patented mix of active and natural ingredients act as a barrier against infections and can also alleviate the symptoms of flu and colds. The anti-viral sprays create a protective film on the mucous membrane in the upper respiratory tract to neutralize viruses and prevent multiplication.
For more information visit ViroStop website. The nasal and oral sprays are available online at Stressnomore.co.uk and can also be purchased at fytofontana.com .
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REV Ocean Appoints Paul Baribault as CEO Ahead of 2027 Global Operations29.10.2026 15:45:00 CET | Press release
Global conservation and philanthropic leader to spearhead REV Ocean's next chapter, connecting world-class science with international collaboration and ocean protection REV Ocean has appointed Paul Baribault as Chief Executive Officer as the organization moves towards the international debut of its 195-metre research vessel in Rio de Janeiro in April 2027, alongside the UN Ocean Decade Conference. One of the world's largest privately owned research and exploration vessels, REV represents a major philanthropic investment in ocean science. With nine laboratories, advanced deep-sea exploration vehicles and dedicated collaboration facilities, it is designed to give scientists access to world-class research infrastructure and connect their discoveries with the people and institutions able to drive ocean protection. Baribault joins as REV Ocean moves from a decade of engineering and construction into international operations. His mandate will be to build the international partnerships, fundi
Holder Partners Launches Strategic Communications Practice and Appoints Ali Ponte as Director and Practice Lead29.10.2026 15:15:00 CET | Press release
The new practice connects strategic communications and stakeholder engagement with Holder Partners’ capabilities in investigations, disputes, cybersecurity, due diligence and risk advisory. Holder Partners, a multidisciplinary consulting and advisory firm, today announced the launch of its Strategic Communications practice and the appointment of Ali Ponte as Director and Practice Lead. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027701219/en/ Ali Ponte, Director and Practice Lead of Holder Partners’ Strategic Communications practice. The practice advises leading companies and institutions, their boards, senior executives and counsel on communications, reputation and stakeholder considerations in complex matters and periods of significant change or opportunity. Each engagement is tailored to the client’s objectives and, where relevant, draws on Holder Partners’ broader advisory capabilities. Its strategic counsel, infor
Accertify Formalizes Partner Ecosystem as Fraud, Payments, and Chargebacks Converge Into a Single Risk Surface29.10.2026 15:00:00 CET | Press release
New partner program brings payment providers, orchestrators, commerce platforms, and consultancies together around the industry's largest fraud data community Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the launch of the Accertify Partner Program, a formalized partnership ecosystem connecting payment providers, orchestrators, commerce platforms, and consultancies to Accertify’s network-powered fraud intelligence. Partners can join through two tracks. The Referral track lets partners make a single introduction while Accertify handles the sale, implementation, and support. The Reseller track lets partners sell Accertify on their own contract and own the client relationship and margin. Partners that integrate with Accertify follow a defined certification path, so clients get a tested, supported connection from day one. Every client a partner brings joins a conso
Draslovka to Acquire ex-Natron Energy Battery IP, Completing a Vertically Integrated Western Sodium-Ion Value Chain29.10.2026 14:30:00 CET | Press release
Acquisition gives Draslovka control of former Natron Energy IP portfolio spanning sodium-ion materials, cells and complete battery systems. Deal combines acquired IP with Draslovka’s existing chemistry and European cathode-material capabilities, bringing key parts of the sodium-ion value chain together within one Western-aligned group and its partners. The IP acquisition strengthens Draslovka’s position across the emerging Western sodium-ion battery value chain. Technology targets applications where safety, high power, long cycle life and performance across a wide temperature range are critical, including data centers, grid storage, defense, industrial fleets, telecoms, rail and aviation. The acquired IP will substantively boost Draslovka’s technology offering, a portfolio of transformative and protected innovations for specific industries. Draslovka’s US-based subsidiary, COVORO MINING SOLUTIONS LLC (Covoro), the operator of one of the largest solid sodium cyanide plants in the world,
Veracode Finds First Meaningful Gain in AI Code Security Since 2025 as Average Pass Rate Hits 62%29.10.2026 14:27:00 CET | Press release
October 2026 Study: Anthropic’s Claude Opus 5.5 and OpenAI’s GPT-6-Sol Jointly Lead at a Record 73%, Breaking the Previous High of 68% Veracode, the global leader in application risk management, today announced a jump from 56 percent to 62 percent in overall AI-generated code security, alongside a drop in vulnerabilities from 44 percent to 38 percent — the most significant improvement since the GenAI Code Security Report series began in July 2025. Anthropic's Claude Opus 5.5 and OpenAI's GPT-6-Sol co-lead the rankings at 73 percent, surpassing the previous high of 68 percent set by GPT-5.5 in July 2026. “We’ve been analysing code generated by multiple LLMs for more than a year. Until now, we have not seen a marked improvement in AI code security, despite consistently near-perfect functionality,” said Chris Wysopal, Co-founder & Chief Security Evangelist at Veracode. “This is the first time since running our study that we’ve been able to report a meaningful move on the security dial. Te
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom